Broadcasting the latest developments in GU cancer
Silke joins us to discuss some important data being presented in prostate cancer. Brian and Tom also cover the RCC data at ESMO 2025
Tom and Brian preview the practice-changing bladder cancer data to be presented at ESMO 2025 in Berlin
Jonathan Rosenberg returns to finish this two-part series on IO drug development in urothelial cancer
Jonathan Rosenberg joins in this 2-part series on the history of IO-based therapy in Urothelial Cancer
Gert Attard joins the show to discuss his recent Cell publication looking at tumor transcriptome-wide expression classifiers in advanced prostate cancer.
Christian Kollmannsberger joins us to walk through decades of advances in advanced testis cancer.
Erdafitinibがついに承認されましたが、依然として多くのCQが残されています。日常診療に役立つ最新のデータをもとに、その活用法についてディスカッションしました。
We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.
The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.
Danny Heng joins to tour through VEGF TKI drug development from sorafenib to tivozanib and everything in between.
5月に改訂されたASCOのmCRPC薬物療法のガイドラインについて3人でディスカッションしました！！評価はいかに？
Karie Runcie, MD joins us after chairing the ASCO 2025 rapid oral session to discuss the rcc/bladder presentations.
Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.
Chris Booth joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program after adjuvant chemo in colorectal cancer. We discuss implications for GU and other malignancies.
Brian, Tom and Silke discuss their highlights form ASCO 2025
Josh Meeks joins us to give stellar overview of the emerging data in this space. We also discuss the recent ODAC ruling for lower risk patients.
Gert Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025
Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone
Jorge Garcia joins us to discuss the process of selecting abstracts for oral presentation and select highlights from this session.
Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.
Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.
Jeannie Hoffman-Censits discusses her randomized phase 2 adding SG to maintenence avelumab in mUC.
Michiel Van Der Heijden joins us to discuss the Ipi/Nivo vs chemo randomization in this trial from his ASCO 2025 presentation
Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.
David McDermott joins us on the heels of his outstanding discussion of the clinical science symposium on RCC biomarkers.
Practice Changing? 独断と偏見で選んだ注目演題について結果の予想も含めて議論しました。
Silke, Tom and Brian discuss what they are looking forward to at ASCO 2025
日本と海外の違いはあるのか？mHSPCとmCRPCのUromigos Scoreについて激論！！
Edición especial en castellano con Alfonso Gómez de Liaño y Guillermo de Velasco. David Lorente da su visión sobre el nuevo Uromigos Score, que clasifica distintas opciones de tratamiento en varios escenarios de cáncer de próstata metastásico
Silke and Chris joins us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Several interesting themes emerge.
Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC
Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1. We discuss definitions of CR and regulatory issues around drug approval in this space as well.
Viktor Grunwald joins to discuss the new data session from EIKCS
Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC
Neal Shore joins the show to discuss these exciting data from the American Urological Association Annual Meeting
今月Eur Urol OncolにPublishされたヨーロッパのエキスパートによるmRCCのコンセンサスについて日本との違いについて深い議論をしました！！
Part 2 of our series dives deeper into the explosion of ADC clinical drug development in China
Drs. Dingwei Ye and Yao Zhu from China join the show to talk about drug development in China amid the recent surge of GU clinical trials.
Drs. Alicia Morgans and Chuck Ryan join the show to talk about their new podcast.
Elena Castro joins Tom and Brian on the day after Pluvicto approval pre-chemotherapy in the US to discuss the PSMA Fore data and application in clinical practice.
Ignacio Duran continues his discussion with Brian and Tom regarding novel ADCS in bladder cancer
Cristina Suárez analiza los próximos ensayos clínicos que podrían transformar el manejo del cáncer renal en los próximos años: nuevas combinaciones adyuvantes y estrategias perioperatorias, el uso de tripletes enprimera línea y la integración de inhibidores de HIF con TKIs, entre otros.
Ignacio Duran joins the show to discuss the landscape of established ADCs in urothelial cancer and challenges of drug development in this setting.
Live from the Canary Islands 'Big Idea' talk from Tom, we discuss the new Uromigos Score which ranks different treatment options in several urothelial cancer settings.
Dr. John Heymach from MD Andersons joins us to discuss a novel PD1/VEGF bispecific agent in lung cancer and if there are applicaitons in GU malignancies.
Chuck Ryan joins us to discuss his interview with Felix and reflects on his keynote address at ASCO GU 2025.
Silke Gillessen joins us to discuss the top areas of consensus and controversy from APCCC 2025
尿路上皮癌と腎癌の臨床に影響を与えるエビデンスをどう解釈するか!?
ASCOGU2025で発表された臨床試験の結果の解釈について忖度なしに議論しました！！
Tyler Seibert from UCSD joins the show live from Lugano to discuss meeting highlights and controversies (and his favorite run along the water..)
© 2020-2025 Ivy Podcast Discovery LLC
